https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-03T22:00:00.000Z Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) https://www.biopharmawatch.com/news/APMD/apnimed-upsized-ipo-2026 BiopharmaWatch en 2026-08-03T20:35:00.000Z Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-03T20:30:00.000Z Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HSTM/healthstream-announces-second-quarter-2026-results BiopharmaWatch en 2026-08-03T20:30:00.000Z HealthStream Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-mark-anquillare-board BiopharmaWatch en 2026-08-03T20:30:00.000Z Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors https://www.biopharmawatch.com/news/CV/capso-vision-launch-ai-highlights BiopharmaWatch en 2026-08-03T20:30:00.000Z CapsoVision® Announces International Launch of AI Highlights https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-record-q2-results BiopharmaWatch en 2026-08-03T20:15:00.000Z UFP Technologies Announces Record Q2 Results https://www.biopharmawatch.com/news/TFX/teleflex-divestiture-oem-business-1-5-billion BiopharmaWatch en 2026-08-03T20:15:00.000Z Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion https://www.biopharmawatch.com/news/HAE/vascade-mvp-xl-effectiveness-electrophysiology-procedures BiopharmaWatch en 2026-08-03T20:15:00.000Z New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths https://www.biopharmawatch.com/news/AEON/aeon-biopharma-regains-compliance-nyse-american BiopharmaWatch en 2026-08-03T20:15:00.000Z AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-business-update-q2-2026 BiopharmaWatch en 2026-08-03T20:15:00.000Z CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SEER/seer-participate-canaccord-genuity-growth-conference BiopharmaWatch en 2026-08-03T20:15:00.000Z Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/SIBN/si-bone-reports-q2-2026-results-and-guidance BiopharmaWatch en 2026-08-03T20:09:00.000Z SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance https://www.biopharmawatch.com/news/ADUS/addus-homecare-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z Addus HomeCare Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/WGS/genedx-reports-q2-2026-results BiopharmaWatch en 2026-08-03T20:05:00.000Z GeneDx Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HIT/health-in-tech-q2-2026-financial-results-announcement BiopharmaWatch en 2026-08-03T20:05:00.000Z Health In Tech to Announce Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates https://www.biopharmawatch.com/news/SEER/seer-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z Seer to Report Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-03T20:05:00.000Z Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LGVN/longeveron-report-2026-q2-results-conference-call BiopharmaWatch en 2026-08-03T20:05:00.000Z Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 https://www.biopharmawatch.com/news/GUTS/fractyl-health-q2-2026-financial-results-update BiopharmaWatch en 2026-08-03T20:05:00.000Z Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q2-2026-results BiopharmaWatch en 2026-08-03T20:02:00.000Z Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan https://www.biopharmawatch.com/news/VRTX/vertex-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:01:00.000Z Vertex Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-q2-2026-results-updates BiopharmaWatch en 2026-08-03T20:01:00.000Z Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:01:00.000Z Keros Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARGX/argenx-extraordinary-general-meeting-september-2026 BiopharmaWatch en 2026-08-03T20:01:00.000Z argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q2-2026-results-update BiopharmaWatch en 2026-08-03T20:00:00.000Z ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 https://www.biopharmawatch.com/news/HQY/healthequity-second-quarter-earnings-release BiopharmaWatch en 2026-08-03T20:00:00.000Z HealthEquity Announces Second Quarter Earnings Release Date and Investor Conference Schedule https://www.biopharmawatch.com/news/HCSG/community-health-center-services-explained BiopharmaWatch en 2026-08-03T19:11:00.000Z In HelloNation, Healthcare Services Expert Sheila A. Berschauer Explains What a Community Health Center Can Help With https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-income-growth-q2-2026 BiopharmaWatch en 2026-08-03T18:20:00.000Z Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-appoints-cassie-mclean-ceo-care-delivery BiopharmaWatch en 2026-08-03T18:20:00.000Z Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery https://www.biopharmawatch.com/news/XCUR/exicure-settle-gpcr-therapeutics-milestone-payment BiopharmaWatch en 2026-08-03T13:24:00.000Z Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance https://www.biopharmawatch.com/news/REVB/gemini-market-assessment-acute-kidney-injury BiopharmaWatch en 2026-08-03T13:00:00.000Z Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T13:00:00.000Z Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-expands-ip-portfolio-antivirals BiopharmaWatch en 2026-08-03T13:00:00.000Z Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform https://www.biopharmawatch.com/news/SBC/sbc-medical-2q-2026-financial-results-announcement BiopharmaWatch en 2026-08-03T13:00:00.000Z SBC Medical to Announce 2Q 2026 Financial Results https://www.biopharmawatch.com/news/AIM/aim-immunotech-last-dose-duripanc-clinical-trial BiopharmaWatch en 2026-08-03T12:33:00.000Z AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-evotec-nb4168-preclinical-development BiopharmaWatch en 2026-08-03T12:32:00.000Z Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 https://www.biopharmawatch.com/news/ACOG/alpha-cognition-report-q2-2026-results BiopharmaWatch en 2026-08-03T12:30:00.000Z Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update https://www.biopharmawatch.com/news/OMER/cms-grants-ntap-status-yartemlea BiopharmaWatch en 2026-08-03T12:30:00.000Z CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® https://www.biopharmawatch.com/news/ADGM/adagio-medical-first-patient-ulta-system BiopharmaWatch en 2026-08-03T12:30:00.000Z Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-appoints-new-leaders-cmc-supply-chain-quality BiopharmaWatch en 2026-08-03T12:30:00.000Z Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-interference-study-fingerprinting BiopharmaWatch en 2026-08-03T12:30:00.000Z Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System https://www.biopharmawatch.com/news/CUE/cue-biopharma-appoints-james-ahlers-cfo-ind-submission BiopharmaWatch en 2026-08-03T12:30:00.000Z Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-cad-1005-strategy-update BiopharmaWatch en 2026-08-03T12:30:00.000Z Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation https://www.biopharmawatch.com/news/VERU/veru-report-fiscal-2026-third-quarter-results BiopharmaWatch en 2026-08-03T12:30:00.000Z Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-astro-2026 BiopharmaWatch en 2026-08-03T12:05:00.000Z Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 https://www.biopharmawatch.com/news/CMND/clearmind-acquires-majority-stake-ev-wireless-charging BiopharmaWatch en 2026-08-03T12:02:00.000Z Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company https://www.biopharmawatch.com/news/TSHA/taysha-catalent-partnership-tsha-102-rett-syndrome BiopharmaWatch en 2026-08-03T12:00:13.000Z Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-q2-2026-earnings-release BiopharmaWatch en 2026-08-03T12:00:00.000Z Sonida Senior Living Announces Second Quarter Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-jessica-cohen-pfeffer BiopharmaWatch en 2026-08-03T12:00:00.000Z Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-activates-oregon-health-science-university BiopharmaWatch en 2026-08-03T12:00:00.000Z Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/ACXP/fda-guidance-acurx-ibezapolstat-phase-3-trial BiopharmaWatch en 2026-08-03T12:00:00.000Z FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-chief-legal-officer BiopharmaWatch en 2026-08-03T12:00:00.000Z CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer https://www.biopharmawatch.com/news/AKBA/akebia-phase-2-trial-ebribafusp-kidney-diseases BiopharmaWatch en 2026-08-03T12:00:00.000Z Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases https://www.biopharmawatch.com/news/DSGN/design-therapeutics-restore-fa-update-q2-2026-results BiopharmaWatch en 2026-08-03T12:00:00.000Z Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALT/altimmune-performa-phase-3-trial-pemvidutide-mash BiopharmaWatch en 2026-08-03T12:00:00.000Z Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH https://www.biopharmawatch.com/news/AVXL/anavex-refresh-board-stockholder-value-creation BiopharmaWatch en 2026-08-03T12:00:00.000Z Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation https://www.biopharmawatch.com/news/STIM/neuronetics-chernett-shared-vision BiopharmaWatch en 2026-08-03T12:00:00.000Z Neuronetics and Jorey Chernett Announce Shared Vision https://www.biopharmawatch.com/news/CARL/carlsmed-favorable-reimbursement-aprevo-lumbar BiopharmaWatch en 2026-08-03T12:00:00.000Z Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-03T12:00:00.000Z Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/LPCN/lipocine-appoints-michael-grissinger-board-directors BiopharmaWatch en 2026-08-03T12:00:00.000Z Lipocine Appoints Michael J. Grissinger to Board of Directors https://www.biopharmawatch.com/news/LLY/lilly-olomorasib-fda-breakthrough-therapy-designation BiopharmaWatch en 2026-08-03T11:45:00.000Z Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer https://www.biopharmawatch.com/news/LNTH/curium-lantheus-merger-agreement BiopharmaWatch en 2026-08-03T11:38:00.000Z Curium Announces Definitive Agreement to Merge with Lantheus https://www.biopharmawatch.com/news/LTRN/lantern-pharma-open-medicine-ai-launch BiopharmaWatch en 2026-08-03T11:30:00.000Z Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine https://www.biopharmawatch.com/news/BBIO/bridgebio-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-03T11:30:00.000Z BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-arimoclomol-npc-real-world-data BiopharmaWatch en 2026-08-03T11:30:00.000Z Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) https://www.biopharmawatch.com/news/MDCX/medicus-pharma-appoints-dr-faisal-mehmud-ceo-antev-limited BiopharmaWatch en 2026-08-03T11:30:00.000Z Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-conference-call-august-2026 BiopharmaWatch en 2026-08-03T11:30:00.000Z ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-q3-results BiopharmaWatch en 2026-08-03T11:15:00.000Z Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-august-2026 BiopharmaWatch en 2026-08-03T11:05:00.000Z REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/CANF/can-fite-clinical-program-piclidenoson-lowe-syndrome BiopharmaWatch en 2026-08-03T11:00:00.000Z Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-positive-safety-update-rp-a501 BiopharmaWatch en 2026-08-03T11:00:00.000Z Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease https://www.biopharmawatch.com/news/ZLAB/fda-orphan-drug-designation-zai-lab-zoci BiopharmaWatch en 2026-08-03T11:00:00.000Z U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/CGEN/compugen-reports-q2-2026-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Compugen Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/GNPX/genprex-collaboration-roche-biomarker-assay-validation BiopharmaWatch en 2026-08-03T11:00:00.000Z Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-q2-2026-financial-results-briumvi-guidance BiopharmaWatch en 2026-08-03T11:00:00.000Z TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-3-trial-opgx-lca5-enrollment-complete BiopharmaWatch en 2026-08-03T11:00:00.000Z Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-4800-fda-meeting BiopharmaWatch en 2026-08-03T11:00:00.000Z Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q2-2026-financial-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ANL/adlai-nortye-phase-i-trial-an4035-australia BiopharmaWatch en 2026-08-03T11:00:00.000Z Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia https://www.biopharmawatch.com/news/CBLL/ceribell-cms-ntap-delirium-monitor BiopharmaWatch en 2026-08-03T11:00:00.000Z Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q2-2026-results BiopharmaWatch en 2026-08-03T11:00:00.000Z Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-opko-health-investment-norovirus-data BiopharmaWatch en 2026-08-03T11:00:00.000Z Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T10:50:00.000Z Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/SUPN/supernus-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-03T10:35:00.000Z Supernus Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DRIO/dariohealth-q2-2026-results-conference-call BiopharmaWatch en 2026-08-03T10:30:00.000Z DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/SUPN/supernus-indivior-merger-cns-biopharmaceutical-leader BiopharmaWatch en 2026-08-03T10:30:00.000Z Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale https://www.biopharmawatch.com/news/PCVX/online-education-transformation-pandemic BiopharmaWatch en 2026-08-03T10:08:58.000Z Почему онлайн-обучение превратилось новой нормой https://www.biopharmawatch.com/news/BNTX/biontech-appoints-dr-guido-oelkers-ceo BiopharmaWatch en 2026-08-03T09:00:00.000Z BioNTech ernennt Dr. Guido Oelkers zum neuen Vorstandsvorsitzenden https://www.biopharmawatch.com/news/BNTX/biontech-appoints-guido-oelkers-ceo BiopharmaWatch en 2026-08-03T09:00:00.000Z BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer https://www.biopharmawatch.com/news/OCS/oculis-positive-fda-feedback-privosegtor-ms-relapses BiopharmaWatch en 2026-08-03T08:00:00.000Z Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-03 BiopharmaWatch en 2026-08-03T07:17:36.944Z Biotech Catalysts to Watch: Key Developments for August 2026 https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-08-03T07:16:57.252Z FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-08-03T07:16:15.359Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/blog/fda-calendar-august-2026 BiopharmaWatch en 2026-08-03T07:15:41.154Z FDA Calendar August 2026: Key PDUFA Dates and Analysis